Revankar, Sanjay G.

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

Kuderer, N. M., Choueiri, T. K., Shah, D. P., Shyr, Y., Rubinstein, S. M., Rivera, D. R., Shete, S., Hsu, C.-Y., Desai, A., de Lima Lopes, G., et al. (2020) · The Lancet

COVID-19 and healthcare impactsCOVID-19 Clinical Research Studies

Cited by 1,726

Interpretation of Trailing Endpoints in Antifungal Susceptibility Testing by the National Committee for Clinical Laboratory Standards Method

Revankar, S. G., Kirkpatrick, W. R., McAtee, R. K., Fothergill, A. W., Redding, S. W., Rinaldi, M. G., & Patterson, T. F. (1998) · Journal of Clinical Microbiology

Antifungal resistance and susceptibilityBacterial Identification and Susceptibility Testing

Cited by 133

MSG-10: a Phase 2 study of oral ibrexafungerp (SCY-078) following initial echinocandin therapy in non-neutropenic patients with invasive candidiasis

Spec, A., Pullman, J., Thompson, G. R., Powderly, W. G., Tobin, E. H., Vazquez, J., Wring, S. A., Angulo, D., Helou, S., Pappas, P. G., et al. (2019) · Journal of Antimicrobial Chemotherapy

Antifungal resistance and susceptibilityFungal Infections and Studies

Cited by 88

A Mycoses Study Group International Prospective Study of Phaeohyphomycosis: An Analysis of 99 Proven/Probable Cases.

Revankar, S. G., Baddley, J. W., Chen, S. C. A., Kauffman, C. A., Slavin, M., Vazquez, J. A., Seas, C., Morris, M. I., Nguyen, M. H., Shoham, S., et al. (2017) · Open Forum Infectious Diseases

Fungal Infections and StudiesAntifungal resistance and susceptibility

Cited by 67

A randomized trial of continuous or intermittent therapy with fluconazole for oropharyngeal candidiasis in HIV-infected patients: clinical outcomes and development of fluconazole resistance

Revankar, S. G., Kirkpatrick, W. R., McAtee, R. K., Dib, O. P., Fothergill, A. W., Redding, S. W., Rinaldi, M. G., Hilsenbeck, S. G., & Patterson, T. F. (1998) · The American Journal of Medicine

Antifungal resistance and susceptibilityHIV/AIDS oral health manifestations

Cited by 67

Trailing end-point phenotype of Candida spp. in antifungal susceptibility testing to fluconazole is eliminated by altering incubation temperature

Agrawal, D., Patterson, T. F., Rinaldi, M. G., & Revankar, S. G. (2007) · Journal of Medical Microbiology

Antifungal resistance and susceptibilityBacterial Identification and Susceptibility Testing

Cited by 30